What types of molecules can be optimized with this service?

Our automated lead optimization platform is designed for small molecules, antibodies, enzymes, peptides, and vaccines. The specific workflow and assays are customized to the molecular modality and target profile during consultation.

How do you integrate client-provided data and knowledge?

We incorporate existing structure-activity data, target biology, and preclinical requirements into our computational models and study designs. A kick-off meeting establishes data-sharing protocols and project milestones.

Can the service handle parallel optimization of multiple chemical series?

Yes, our automated infrastructure and iterative workflow are designed to advance several series simultaneously. The capacity and prioritization are scoped per project to balance resource allocation and timeline goals.

What in vivo studies are included in the optimization workflow?

Typical in vivo studies include rodent pharmacokinetics and pharmacodynamics, efficacy in disease-relevant models, and exploratory non-GLP toxicology. The exact package is determined by the target product profile and regulatory stage.

How do you ensure data quality across the automated workflow?

All assays undergo validation with reference controls, and automated data capture reduces transcription errors. In-study QC checks and periodic performance reviews maintain reproducibility and reliability.

Is the service suitable for programs already in late-stage lead optimization?

Yes, the platform can be applied at any stage of lead optimization. For late-stage compounds, we focus on fine-tuning ADME, safety, and in vivo efficacy while minimizing synthetic iteration cycles.

Services

Online Inquiry

Name *

Email *

Subject *

Phone

Your Message

How Did You Hear About Us

Automated Lead Optimization

Accelerate preclinical candidate selection through integrated computational modeling, automated synthesis, and iterative in vitro/in vivo.

Iterative computational modeling and machine learning predictions
Automated compound management and parallel synthesis of analog libraries
High-throughput in vitro assays for potency, selectivity, and ADME profiling
In vivo pharmacokinetic, pharmacodynamic, and safety studies
Translational study design and risk mitigation for candidate selection

Discuss Your Project

How can automated lead optimization shorten your preclinical timeline?

Our integrated platform combines computational design, automated synthesis, and iterative testing to systematically optimize lead properties while reducing manual effort and cycle times.

Potency and selectivity optimization across chemical series
ADME and safety profiling integrated into each iteration
Real-time SAR analysis to guide subsequent designs
In vivo efficacy and pharmacokinetic validation
Candidate selection criteria aligned with target product profile

Integrated

Automated

Iterative

Our Approach

Integrated Automated Lead Optimization Workflow

We combine computational prediction, automated synthesis, and multi-parameter profiling to systematically advance leads toward preclinical candidates with built-in translational foresight.

Computational Design & Automated Synthesis

AI/ML models predict compound properties and guide prioritization, while automated synthesis platforms generate focused analog libraries for testing.

Structure-based and ligand-based modeling
Machine learning ADME and toxicity predictions
Automated compound management and sample preparation
Parallel synthesis of targeted analog series
Iterative learning from assay data to refine models

Integrated In Vitro & In Vivo Profiling

High-throughput assays assess potency, selectivity, ADME, and safety in parallel, with in vivo PK/PD and efficacy studies providing translational context.

Potency and selectivity panels (enzyme, cellular, counterscreens)
ADME suite (solubility, permeability, metabolic stability, CYP inhibition)
hERG and cytotoxicity screening
Rodent PK and PK/PD studies
Efficacy in disease-relevant animal models

Assay Quality & Reproducibility

Each assay is validated with robust controls and automated data capture to minimize variability and ensure reliable SAR data.

Data Analytics & SAR Modeling

Advanced statistical analyses and visualization tools identify key structure-activity relationships and guide compound prioritization.

Translational Readiness

Study designs incorporate human-relevant models, biomarkers, and dose predictions to de-risk progression to clinical development.

Deliverables

Comprehensive Data and Reporting Packages

Each project delivers detailed raw data, integrated SAR analyses, and a final candidate nomination report that supports regulatory filings.

Data Deliverables

Potency and selectivity data (IC50, EC50, Ki)
ADME profile (solubility, permeability, metabolic stability, PPB, CYP)
In vivo PK parameters and PK/PD relationships
Safety data (hERG, cytotoxicity, genotoxicity)
SAR tables and interactive visualization files

Reporting & Support

Integrated lead optimization report with candidate ranking
Translational study summary and human dose predictions
Patent support documentation
Regular project teleconferences with experienced medicinal chemists

Service Scope

Configurable for Your Program

Our automated lead optimization service is scoped per project to align with your target profile, chemistry stage, and regulatory timeline.

Parameter	Typical Project Scope
Compound Series	Customer-provided lead series or hit matter
Number of Analogs per Cycle	Scoped per project based on SAR needs
Assay Panel	Customized panel including potency, selectivity, ADME, and safety assays
In Vivo Studies	Rodent PK/PD and efficacy models as required
Toxicology	Non-GLP exploratory toxicology studies when selected
Computational Modeling	Structure-based and ML models tailored to target
Project Timeline	Determined during consultation

Workflow

Rapid, Iterative Cycles from Design to Candidate

Each project follows a structured cycle of design, synthesize, test, and analyze—automated to accelerate learning and reduce cycle times.

Computational Model & Design

Leverage structure-based modeling and machine learning to predict potent, selective, and ADME-favorable compounds for synthesis.

Automated Synthesis & Compound Management

Automated parallel synthesis and compound management systems prepare focused analog libraries under controlled conditions.

High-Throughput In Vitro Profiling

Screen compounds against potency, selectivity, ADME, and safety assays in an automated, miniaturized format for rapid data generation.

Iterative SAR Analysis & Prioritization

Analyze multi-parameter data to identify structure-activity relationships; computational models update to guide the next design cycle.

In Vivo Validation & Candidate Selection

Selected compounds progress to in vivo PK/PD, efficacy, and exploratory toxicology studies; data inform final candidate choice against agreed criteria.

Applications

Optimized for Diverse Modalities

Our automated lead optimization platform supports small molecules, biologics, peptides, and vaccines, adapting the workflow to each modality's unique requirements.

Rapid optimization of small-molecule leads

Iterative medicinal chemistry cycles driven by ML predictions and automated synthesis accelerate progression from hit to preclinical candidate.

Potency and selectivity optimization across multiple series
ADME and PK profiling integrated into each round
Non-GLP toxicology studies for early go/no-go decisions

Enhance biotherapeutic properties through machine-learning-guided design

Our platform applies ML-driven protein engineering to optimize affinity, developability, and immunogenicity profiles.

Affinity maturation and epitope binning
Developability assessment (expression, stability, aggregation)
Immunogenicity risk prediction and reduction

Optimize peptide stability, potency, and selectivity

Automated synthesis and high-throughput screening enable rapid SAR exploration for peptide therapeutics and vaccine antigens.

Peptide stability and bioavailability improvement
Target binding and selectivity optimization
Vaccine antigen design and immunogenicity profiling

FAQ

Frequently Asked Questions

Common questions about our automated lead optimization service capabilities, scope, and process.

Our automated lead optimization platform is designed for small molecules, antibodies, enzymes, peptides, and vaccines. The specific workflow and assays are customized to the molecular modality and target profile during consultation.
We incorporate existing structure-activity data, target biology, and preclinical requirements into our computational models and study designs. A kick-off meeting establishes data-sharing protocols and project milestones.
Yes, our automated infrastructure and iterative workflow are designed to advance several series simultaneously. The capacity and prioritization are scoped per project to balance resource allocation and timeline goals.
Typical in vivo studies include rodent pharmacokinetics and pharmacodynamics, efficacy in disease-relevant models, and exploratory non-GLP toxicology. The exact package is determined by the target product profile and regulatory stage.
All assays undergo validation with reference controls, and automated data capture reduces transcription errors. In-study QC checks and periodic performance reviews maintain reproducibility and reliability.
Yes, the platform can be applied at any stage of lead optimization. For late-stage compounds, we focus on fine-tuning ADME, safety, and in vivo efficacy while minimizing synthetic iteration cycles.

Scientific Literature

References

Li GB, Ji S, Yang LL, et al. LEADOPT: an automatic tool for structure-based lead optimization, and its application in structural optimizations of VEGFR2 and SYK inhibitors. European journal of medicinal chemistry. 2015;93:523-38. View on PubMed
Quintero C, Kariv I. Design and implementation of an automated compound management system in support of lead optimization. Journal of biomolecular screening. 2009;14(5):499-508. View on PubMed

Please kindly note that our products and services are for research use only.